Company Overview
Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +25.21% |
| 6 Months: | -42.26% |
| 3 Months: | -20.64% |
| 1 Month: | -18.03% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)42.17 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 54.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | CELC Celcuity Inc. R2KR3KPHARMA | 65.57 | -15.21 | $3.21B | 0.00% | -40.76% | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,306.69 | 43.95 | $1.16T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 267.61 | 31.05 | $644.91B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 285.19 | 80.56 | $503.96B | 2.54% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 424.98 | 27.29 | $381.46B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPXR3KPHARMA | 147.24 | 117.79 | $363.27B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 7 | NVS Novartis AG PHARMA | 156.27 | 23.61 | $297.02B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 172.57 | 25.80 | $267.64B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 676.54 | 36.45 | $250.15B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -877.54K | -993.91K | -1.61M | -1.53M | -2.08M | -1.93M | -1.98M | -1.97M | -1.84M | -2.09M | -2.31M | -2.21M | -2.48M | -2.79M | -13.64M | -5.60M | -7.51M | -9.60M | -10.64M | -12.55M | -15.06M | -18.90M | -22.49M | -24.28M | -30.06M | -36.13M | -44.01M | -42.85M | -50.51M |
| Net Income | -868.52K | -987.35K | -1.78M | -1.76M | -1.97M | -1.82M | -1.87M | -1.85M | -1.72M | -1.98M | -2.25M | -2.20M | -2.47M | -2.79M | -14.03M | -6.03M | -7.93M | -9.96M | -10.89M | -11.94M | -14.59M | -18.40M | -21.61M | -23.72M | -29.79M | -37.00M | -45.27M | -43.80M | -52.84M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.67 | -0.75 | -0.55 | -0.66 | -0.83 | -0.64 | -0.62 | -0.70 | -0.86 | -1.04 | -0.92 | -0.97 |
| R&D Expense | 812.80K | 908.77K | 1.30M | 1.36M | 1.55M | 1.55M | 1.60M | 1.59M | 1.47M | 1.71M | 1.85M | 1.77M | 1.96M | 2.24M | 13.07M | 4.96M | 6.70M | 8.37M | 9.62M | 11.28M | 13.75M | 17.49M | 20.65M | 22.50M | 27.59M | 29.76M | 40.22M | 34.91M | 33.06M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -3.33M | -5.95M | -7.93M | -7.81M | -9.56M | -28.36M | -39.39M | -66.23M | -113.27M | -172.19M |
| Net Income | -3.31M | -6.25M | -7.48M | -7.36M | -9.47M | -29.61M | -40.37M | -63.78M | -111.78M | -177.04M |
| Diluted EPS | - | - | - | - | - | - | -2.64 | -2.69 | -2.83 | -3.79 |
| R&D Expense | 3.06M | 4.98M | 6.33M | 6.27M | 7.68M | 25.76M | 35.29M | 60.59M | 104.20M | 145.00M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 6.06M | 31.97M | 26.03M | 20.28M | 12.96M | 85.91M | 175.70M | 191.22M | 245.12M | 466.56M |
| Total Equity | 5.02M | 5.61M | 31.39M | 25.35M | 19.30M | 11.70M | 68.71M | 133.77M | 139.77M | 115.62M | 100.56M |
| Cash & Equivalents | 5.07M | 5.86M | 2.69M | 15.94M | 18.74M | 11.64M | 84.29M | 24.57M | 30.66M | 22.52M | 165.70M |
| Long Term Debt | - | - | - | - | - | - | 15.98M | 35.76M | 37.57M | 105.09M | 137.55M |
| Total Liabilities | - | 445.36K | 578.05K | 682.21K | 983.23K | 1.25M | 17.20M | 41.93M | 51.45M | 129.50M | 366.00M |
| Current Liabilities | - | 445.36K | 578.05K | 662.33K | 911.33K | 1.19M | 2.51M | 6.88M | 14.19M | 31.72M | 44.15M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -2.89M | -4.95M | -6.08M | -6.00M | -7.15M | -20.31M | -36.01M | -53.81M | -83.47M | -153.28M |
| Investing Cash Flow | -40.90K | -28.98M | 19.09M | 8.53M | -89.37K | -81.40K | -144.03M | -5.01M | -63.07M | -64.08M |
| Financing Cash Flow | 3.72M | 30.71M | 236.70K | 259.31K | 137.97K | 93.04M | 120.33M | 64.91M | 138.39M | 360.55M |
| Capital Expenditure | -40.90K | -239.85K | -629.61K | 380.20K | -89.37K | -81.90K | -158.77K | -97.64K | -250.00K | -249.00K |
| Free Cash Flow | -2.93M | -5.19M | -6.71M | -5.62M | -7.24M | -20.39M | -36.17M | -53.91M | -83.72M | -153.53M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - | - | - | - |
| ROE % | -59.0% | -19.9% | -29.5% | -38.1% | -81.0% | -43.1% | -30.2% | -45.6% | -96.7% | -176.1% |
| ROCE % | -59.3% | -19.0% | -31.3% | -40.3% | -81.2% | -34.0% | -23.3% | -37.4% | -53.1% | -40.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Baker Bros. Advisors, LP | 16.18% | 7.92M | $537.80M |
| 2 | Avoro Capital Advisors LLC | 6.95% | 3.40M | $231.00M |
| 3 | RTW Investments LP | 6.75% | 3.30M | $224.54M |
| 4 | Perceptive Advisors Llc | 6.53% | 3.20M | $217.22M |
| 5 | Blackrock Inc. | 6.17% | 3.02M | $205.10M |
| 6 | State Street Corporation | 4.00% | 1.96M | $132.84M |
| 7 | Vanguard Capital Management LLC | 3.83% | 1.87M | $127.33M |
| 8 | NEA Management Company, LLC | 3.50% | 1.71M | $116.22M |
| 9 | Soleus Capital Management, L.P. | 3.48% | 1.70M | $115.79M |
| 10 | Bank of America Corporation | 3.01% | 1.47M | $99.96M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for CELC
Celcuity Inc. (CELC) stock price, news, quote and history - Yahoo Finance Singapore
<a href="https://news.google.com/rss/articles/CBMiUkFVX3lxTE5TV0hqTkZFbWZIUlR0UlQ3MENGazhvMXJxcDhMQUUwbmw0dW1RdzVBT00zX0ZGZkFWWWhuS3hDMnhDR25YNTUzaWpDa3RKUkRZN0E?oc=5" target="_blank">Celcuity Inc. (CELC) stock price, news, quote and histor…
Celcuity (CELC) Stock May Be Hard To Value On Book Value - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxNNW9YTF9YTEQ1NWJCTGloRzlzUVctMDByM0VWdUFuUUdOaXZVMFoxVldPS3ExVTdmYXM5cUxLdFpfVUZrQVJFcEE4T3hYT2RPbGkwY2swWVpDclgxOGhPTl9Ea25JbC0wclNSNzBrUVd2NzlpTW5BbGtVTjVsdjdGMlBLemNoWU9NdmxwMk…
Cantor Fitzgerald initiates Celcuity stock with overweight rating - Investing.com
<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxNQnltVVlBQXpiZ09rWlhKSGhMSUs2WDJqbWJVLXZUQVBBU3licVlIN0VyQ1EyUW1oN0FObE0tTENvLXJlZVNhcUxLaFNjOFlLU0ZTVlFzRzEtTEhhSWdhWUMzMzFoOWl3ek9SYno3Yy0zZ3ZyMDNTeFd0djZtQjByNVdCQzViQW8xRWROQV…
CELC Stock Jumps After Hours On Positive Breast Cancer Trial Data - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiywFBVV95cUxPYWE3bEpjVkFoNUZZckMxZEQ1bXVRODFwal9qLWVXREFaR253c0ttdFYtMWMxbkl0MldMdDQtUmI0V0JJZWt5MGhCUEJwcWdCT3N2M21GYzIwcmNsNnliYnRmOXJCZVRvelFhdFRYUFFqYm9wYW1nZldlYTYtQzZjaWFUU21sV3I0UVNpcm…
Celcuity (CELC) Stock May Be Overvalued After REVTORPYK Approval - Webull
<a href="https://news.google.com/rss/articles/CBMiWEFVX3lxTE1VeWJTZ3ZUdlJmeVZVaXE2MXpmTm5CM2ptX3BNZC1valpzRUtWSmxqNVNOMkNTNmJRZlVrRmQtSDNDSHBRNE12WVJvNnZDT1l2ZTQzTF93eGo?oc=5" target="_blank">Celcuity (CELC) Stock May Be Overvalued After RE…
Celcuity (CELC) Slides As Fair Value Debate Builds, Is It Still 65% Undervalued? - Simply Wall Street
<a href="https://news.google.com/rss/articles/CBMi2gFBVV95cUxPck9WU2wwd0hMUmZBRVVXbElFOGd6dGJnSzczVmphel9hak1SWHhqejVOYXdjV2RSenJmTi1RRThkZEdzT1FVRTFNemdHQU9ubnVwclYxTVN5Wk5MV2pLeWpEcTNLVk9YLVJWaXMtUUgwdTdfRXBZaU9IMDBscU5oZGtHeWhyU1lubm1vWU…
CELC — Frequently Asked Questions
What is the current share price of Celcuity Inc. (CELC)?
As of 2026-10-22 16:30 PDT, Celcuity Inc. (CELC) trades at $65.57 on NasdaqCM. Its 52-week range is $45.22 to $144.98.
What is the market capitalisation of CELC?
Celcuity Inc. (CELC) has a market capitalisation of $3.21B on NasdaqCM.
What is the P/E ratio of CELC?
CELC trades at a trailing price-to-earnings (P/E) ratio of -15.21. The industry average P/E is 25.61. Its price-to-book (P/B) ratio is -260.31.
Is CELC a good stock to buy?
This page provides a data-driven analysis of Celcuity Inc. (CELC), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.